FDA Panel Narrowly Backs Compounding Four Peptides
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA's Pharmacy Compounding Advisory Committee (PCAC) narrowly voted on Thursday to recommend allowing compounding pharmacies to manufacture the unapproved peptides BPC-157, KPV, TB-500, and MOTS-c.
- Robert F. Kennedy Jr., the Health Secretary, and peptide proponents are described as winners of the vote, which would lift current restrictions on the drugs.
- The PCAC will vote on additional compounds on Friday, extending the deliberation beyond the initial four peptides.
- The FDA will make the final decision on whether to lift restrictions, and the panel's votes are non-binding — though it is unusual for the agency to go against PCAC recommendations, it has happened at least once before.
- The four peptides are characterized in the source as "little-researched but highly popular" drugs that people have been turning to for health improvement.
Why it matters: If the FDA follows PCAC's recommendation, compounding pharmacies could legally manufacture BPC-157, KPV, TB-500, and MOTS-c, expanding access to drugs the source describes as little-researched but already popular among consumers seeking to improve their health. The narrow vote and the non-binding nature mean the FDA retains final authority, and the panel will weigh additional compounds Friday.
